Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of nirsevimab in healthy adults
NCT02114268Phase 1Completed
- Sponsor
- MedImmune
- Start
- Apr 2014
- Primary completion
- Jun 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nirsevimab in respiratory syncytial virus infection (RSV) (6 arms), sponsored by MedImmune. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs). Started Apr 2014; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02114268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02114268.